The efficacy and safety of @entity11546 , an acetylcholinesterase inhibitor, was evaluated clinically in @entity1 diagnosed with mild to moderate @entity195 ( @entity195 ). This was a prospective, 30-week, multicenter, double-blind, randomized, parallel group, dose-finding study, which included a 2-week screening period, a 12-week treatment period, and follow-up visits at 8 and 16 weeks post-treatment. @entity1 received placebo or @entity11546 once daily. @entity11546 -treated @entity1 received a loading dose of 0.5 mg/kg (25 to 45 mg), 0.9 mg/kg (45 to 80 mg), or 2.0 mg/kg (100 to 180 mg) for 2 weeks, followed by a maintenance dose of 0.2 mg/kg (10 to 20 mg), 0.3 mg/kg (15 to 25 mg), or 0.65 mg/kg (30 to 60 mg) for 10 weeks. Four hundred eighty @entity1 were enrolled. Percentages of @entity1 completing double-blind treatment were 96% in the placebo group and 89 to 94% in the @entity11546 group. @entity11546 significantly improved cognitive ability, as assessed by the @entity195 Assessment Scale-Cognitive Subscale ( @entity11509 -Cog), and enhanced global function, as assessed the Clinicians's Interview-Based Impression of Change with Caregiver Input (CIBIC-Plus). At 3 months, in the intent-to-treat @entity1 , the treatment difference for the change in @entity11509 -Cog score in favor of @entity11546 was 2.94 points (95% CI, 1.61 to 4.27; p = 0.0001). These @entity1 also exhibited a 0.35-point improvement on the CIBIC-Plus relative to the placebo @entity1 (95% CI, 0.15 to 0.54; p = 0.0007). @entity1 receiving lower drug doses had scores intermediate to those of the placebo and the 0.65 mg/kg @entity11546 groups on both performance scales. The drug was well tolerated; side effects were predominantly gastrointestinal in nature, and no hepatic @entity137 was observed. Therefore, in this study, @entity11546 safely improved the @entity73 and benefited the global function of @entity195 @entity1 .

@entity11546 treatment of the @entity73 of XXXX . @entity11546 Study Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity11509 :: ('8540', 'Gene') :: ['ADAS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity11546 :: ('MESH:D014236', 'Chemical') :: ['metrifonate', 'Metrifonate'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive deficits'] @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease", "Alzheimer's Disease"]
@entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']
